BioCentury
ARTICLE | Clinical News

DUSA up on actinic keratosis data

September 14, 2012 12:28 AM UTC

DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.37 to $5.75 on Thursday after Levulan Kerastick followed by DUSA's Blue Light Photodynamic Therapy Illuminator (BLU-U) met the primary endpoint in a Phase II trial in 70 patients with minimally to moderately thick actinic keratosis on the upper extremities. The product produced lesion clearance rates at week 12 of 89% with occlusion (p<0.0001) and 70% without occlusion (p<0.0001) vs. 17% for vehicle control with occlusion and 6% for vehicle without occlusion. Additionally, the use of occlusion significantly improved clearance rates when compared to application without occlusion. Levulan Kerastick is a 20% aminolevulinic acid (ALA) topical photosensitizer solution. ...